1. Diabetes pay-for-performance program can reduce all-cause mortality in patients with newly diagnosed type 2 diabetes mellitus
- Author
-
Chin-Li Lu, Li-Chung Huang, Ching-Fang Tsai, Chieh-Hsiang Lu, and Fang-Ping Kung
- Subjects
Adult ,Male ,medicine.medical_specialty ,Taiwan ,Observational Study ,Comorbidity ,Type 2 diabetes ,Pay for performance ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,pay-for-performance program ,Internal medicine ,Diabetes mellitus ,medicine ,Humans ,In patient ,030212 general & internal medicine ,Reimbursement, Incentive ,Aged ,business.industry ,Mortality rate ,Hazard ratio ,Disease Management ,Type 2 Diabetes Mellitus ,General Medicine ,Middle Aged ,medicine.disease ,Diabetes Mellitus, Type 2 ,Case-Control Studies ,030220 oncology & carcinogenesis ,diabetes mellitus ,Cohort ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,all-cause mortality ,Patient Compliance ,Female ,business ,Research Article - Abstract
Supplemental Digital Content is available in the text, This study aimed to examine the effect of a diabetes pay-for-performance (P4P) program on all-cause mortality in patients with newly diagnosed type 2 diabetes mellitus. Using a Taiwanese representative nationwide cohort, we recruited 5478 patients with newly diagnosed type 2 diabetes enrolled in the P4P program within 5 years after a diagnosis of diabetes between January 1, 2002 and December 31, 2010 and individuals not enrolled in the P4P program were recruited as the control group matched 1:1 with the study group. We used multivariate Cox proportional hazard models analysis to investigate the effect of the P4P program and adherence on all-cause mortality. A total of 250 patients died in the P4P group compared to 395 in the control group (mortality rate 104 vs 169 per 10,000 person-years, respectively, P
- Published
- 2020
- Full Text
- View/download PDF